520
Participants
Start Date
November 1, 2019
Primary Completion Date
May 1, 2023
Study Completion Date
May 1, 2023
Antipsychotic use
Use of first/second generation antipsychotics, use of third-generation antipsychotics, use of aripiprazole specifically
Psychiatric comorbidities
Substance use disorders, cluster B personality disorders, anxiety disorder, major depressive disorder, attention-deficit/hyperactivity disorder, tobacco smoking
Sociodemographics/socioeconomic status
Age, gender identity, ethnicity, highest educational attainment, employment, at school, homelessness, in a relationship
Gambling history
Non-problematic gambling at the time of admission and/or previous 12 months
Clinical variables
Main psychiatric diagnosis, history of psychiatric hospitalizations, severity of illness (CGI-S), functioning (SOFAS), concomitant psychotropic medications use
Montreal University Hospital Center, Montreal
Quebec Mental Health University Institute, Québec
Fonds de la Recherche en Santé du Québec
OTHER_GOV
Laval University
OTHER